A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Neoplasms, Colorectal · Solid Tumor · Colon Cancer · Rectal Cancer · Endometrial Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 14 (final count)
- Started
- Dec 13, 2024
- Main results expected
- Jun 22, 2026
- Fully finished
- Jun 22, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of participants with dose limiting toxicities (DLTs) during DLT observation period
Measured over: Up to 21 days
Part 3: Number of participants with dose limiting toxicities (DLTs) during DLT observation period
Measured over: Up to 21 days
Part 1: Number of participants with treatment emergent adverse events (TEAEs) during DLT observation period
Measured over: Up to 21 days
Part 3: Number of participants with treatment emergent adverse events (TEAEs) during DLT observation period
Measured over: Up to 21 days
Part 1: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs during DLT observation period
Measured over: Up to 21 days
Part 3: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs during DLT observation period
Measured over: Up to 21 days
Part 2: Objective Response Rate (ORR)
Measured over: Up to approximately 26 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06710847 · record last updated 2026-02-02 · checked 2026-11-09 15:47 UTC